The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Iron Chelation Drug Market Research Report 2024
Synopsis
In a healthy body, when the stores of iron are sufficient, the intestines reduce the absorption of this mineral from food and drink to prevent its levels from rising too high.
People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas.
There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition.
The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
The global Iron Chelation Drug market was valued at US$ 715 million in 2023 and is anticipated to reach US$ 430.7 million by 2030, witnessing a CAGR of -6.9% during the forecast period 2024-2030.
Global Iron Chelation Drug key players include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. Global top five manufacturers hold a Revenue Market Share over 35%. Europe accounts for the most Sales Market Share, which have a share over 40%, followed by North America. In terms of product, Deferasirox is the largest segment, with a Revenue Market Share over 90%. And in terms of application, the largest Application is Transfusional Iron Overload, followed by NTDT Caused Iron Overload.
This report aims to provide a comprehensive presentation of the global market for Iron Chelation Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Iron Chelation Drug.
Report Scope
The Iron Chelation Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Iron Chelation Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Iron Chelation Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Chiesi Group
Sun Pharma
Cipla
Natco Pharma
Taro Pharm
Gland Pharma
Segment by Type
Deferasirox
Deferoxamine
Deferiprone
Segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Iron Chelation Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Iron Chelation Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
In a healthy body, when the stores of iron are sufficient, the intestines reduce the absorption of this mineral from food and drink to prevent its levels from rising too high.
People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas.
There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition.
The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
The global Iron Chelation Drug market was valued at US$ 715 million in 2023 and is anticipated to reach US$ 430.7 million by 2030, witnessing a CAGR of -6.9% during the forecast period 2024-2030.
Global Iron Chelation Drug key players include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. Global top five manufacturers hold a Revenue Market Share over 35%. Europe accounts for the most Sales Market Share, which have a share over 40%, followed by North America. In terms of product, Deferasirox is the largest segment, with a Revenue Market Share over 90%. And in terms of application, the largest Application is Transfusional Iron Overload, followed by NTDT Caused Iron Overload.
This report aims to provide a comprehensive presentation of the global market for Iron Chelation Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Iron Chelation Drug.
Report Scope
The Iron Chelation Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Iron Chelation Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Iron Chelation Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Chiesi Group
Sun Pharma
Cipla
Natco Pharma
Taro Pharm
Gland Pharma
Segment by Type
Deferasirox
Deferoxamine
Deferiprone
Segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Iron Chelation Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Iron Chelation Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Iron Chelation Drug Market Overview
1.1 Product Overview and Scope of Iron Chelation Drug
1.2 Iron Chelation Drug Segment by Type
1.2.1 Global Iron Chelation Drug Market Value Comparison by Type (2024-2030)
1.2.2 Deferasirox
1.2.3 Deferoxamine
1.2.4 Deferiprone
1.3 Iron Chelation Drug Segment by Application
1.3.1 Global Iron Chelation Drug Market Value by Application: (2024-2030)
1.3.2 Transfusional Iron Overload
1.3.3 NTDT Caused Iron Overload
1.4 Global Iron Chelation Drug Market Size Estimates and Forecasts
1.4.1 Global Iron Chelation Drug Revenue 2019-2030
1.4.2 Global Iron Chelation Drug Sales 2019-2030
1.4.3 Global Iron Chelation Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Iron Chelation Drug Market Competition by Manufacturers
2.1 Global Iron Chelation Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Iron Chelation Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Iron Chelation Drug Average Price by Manufacturers (2019-2024)
2.4 Global Iron Chelation Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Iron Chelation Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Iron Chelation Drug, Product Type & Application
2.7 Iron Chelation Drug Market Competitive Situation and Trends
2.7.1 Iron Chelation Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Iron Chelation Drug Players Market Share by Revenue
2.7.3 Global Iron Chelation Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Iron Chelation Drug Retrospective Market Scenario by Region
3.1 Global Iron Chelation Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Iron Chelation Drug Global Iron Chelation Drug Sales by Region: 2019-2030
3.2.1 Global Iron Chelation Drug Sales by Region: 2019-2024
3.2.2 Global Iron Chelation Drug Sales by Region: 2025-2030
3.3 Global Iron Chelation Drug Global Iron Chelation Drug Revenue by Region: 2019-2030
3.3.1 Global Iron Chelation Drug Revenue by Region: 2019-2024
3.3.2 Global Iron Chelation Drug Revenue by Region: 2025-2030
3.4 North America Iron Chelation Drug Market Facts & Figures by Country
3.4.1 North America Iron Chelation Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Iron Chelation Drug Sales by Country (2019-2030)
3.4.3 North America Iron Chelation Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Iron Chelation Drug Market Facts & Figures by Country
3.5.1 Europe Iron Chelation Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Iron Chelation Drug Sales by Country (2019-2030)
3.5.3 Europe Iron Chelation Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Iron Chelation Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Iron Chelation Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Iron Chelation Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Iron Chelation Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Iron Chelation Drug Market Facts & Figures by Country
3.7.1 Latin America Iron Chelation Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Iron Chelation Drug Sales by Country (2019-2030)
3.7.3 Latin America Iron Chelation Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Iron Chelation Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Iron Chelation Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Iron Chelation Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Iron Chelation Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Iron Chelation Drug Sales by Type (2019-2030)
4.1.1 Global Iron Chelation Drug Sales by Type (2019-2024)
4.1.2 Global Iron Chelation Drug Sales by Type (2025-2030)
4.1.3 Global Iron Chelation Drug Sales Market Share by Type (2019-2030)
4.2 Global Iron Chelation Drug Revenue by Type (2019-2030)
4.2.1 Global Iron Chelation Drug Revenue by Type (2019-2024)
4.2.2 Global Iron Chelation Drug Revenue by Type (2025-2030)
4.2.3 Global Iron Chelation Drug Revenue Market Share by Type (2019-2030)
4.3 Global Iron Chelation Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Iron Chelation Drug Sales by Application (2019-2030)
5.1.1 Global Iron Chelation Drug Sales by Application (2019-2024)
5.1.2 Global Iron Chelation Drug Sales by Application (2025-2030)
5.1.3 Global Iron Chelation Drug Sales Market Share by Application (2019-2030)
5.2 Global Iron Chelation Drug Revenue by Application (2019-2030)
5.2.1 Global Iron Chelation Drug Revenue by Application (2019-2024)
5.2.2 Global Iron Chelation Drug Revenue by Application (2025-2030)
5.2.3 Global Iron Chelation Drug Revenue Market Share by Application (2019-2030)
5.3 Global Iron Chelation Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Iron Chelation Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Iron Chelation Drug Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Chiesi Group
6.2.1 Chiesi Group Corporation Information
6.2.2 Chiesi Group Description and Business Overview
6.2.3 Chiesi Group Iron Chelation Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Chiesi Group Iron Chelation Drug Product Portfolio
6.2.5 Chiesi Group Recent Developments/Updates
6.3 Sun Pharma
6.3.1 Sun Pharma Corporation Information
6.3.2 Sun Pharma Description and Business Overview
6.3.3 Sun Pharma Iron Chelation Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sun Pharma Iron Chelation Drug Product Portfolio
6.3.5 Sun Pharma Recent Developments/Updates
6.4 Cipla
6.4.1 Cipla Corporation Information
6.4.2 Cipla Description and Business Overview
6.4.3 Cipla Iron Chelation Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cipla Iron Chelation Drug Product Portfolio
6.4.5 Cipla Recent Developments/Updates
6.5 Natco Pharma
6.5.1 Natco Pharma Corporation Information
6.5.2 Natco Pharma Description and Business Overview
6.5.3 Natco Pharma Iron Chelation Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Natco Pharma Iron Chelation Drug Product Portfolio
6.5.5 Natco Pharma Recent Developments/Updates
6.6 Taro Pharm
6.6.1 Taro Pharm Corporation Information
6.6.2 Taro Pharm Description and Business Overview
6.6.3 Taro Pharm Iron Chelation Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Taro Pharm Iron Chelation Drug Product Portfolio
6.6.5 Taro Pharm Recent Developments/Updates
6.7 Gland Pharma
6.6.1 Gland Pharma Corporation Information
6.6.2 Gland Pharma Description and Business Overview
6.6.3 Gland Pharma Iron Chelation Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Gland Pharma Iron Chelation Drug Product Portfolio
6.7.5 Gland Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Iron Chelation Drug Industry Chain Analysis
7.2 Iron Chelation Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Iron Chelation Drug Production Mode & Process
7.4 Iron Chelation Drug Sales and Marketing
7.4.1 Iron Chelation Drug Sales Channels
7.4.2 Iron Chelation Drug Distributors
7.5 Iron Chelation Drug Customers
8 Iron Chelation Drug Market Dynamics
8.1 Iron Chelation Drug Industry Trends
8.2 Iron Chelation Drug Market Drivers
8.3 Iron Chelation Drug Market Challenges
8.4 Iron Chelation Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
